Finance Foggle

FDA Approves Breakthrough Eye Drops That Fix Near Vision Without Glasses Key Takeaways Aspect Details Latest FDA Approval VIZZ eye drops approved July 2025, works up to 10 hours Active Ingredient Aceclidine 1.44% - first of its kind in the US How Long It Works Up to 10 hours per dose with once-daily application Effectiveness 71% of users gained 3+ lines of near vision improvement Availability Expected launch between October-December 2025 Other Options Vuity (pilocarpine) and QLOSI also FDA-approved Who Can Use It Adults with presbyopia (age-related near vision loss) Cost Coverage Insurance coverage varies, prescription required What Are These Revolutionary Eye Drops? The FDA just approved VIZZ, the first and only aceclidine-based eye drop for treating presbyopia, marking a global first in this treatment category. This isn't your grandfather's reading glasses solution - we're talking about drops that can give you clear near vision for up to 10 hours with just one d...

Trump Administration Weight Loss Drug Pilot: Medicare & Medicaid Coverage for Ozempic, Wegovy in 2026-2027 - GLP-1 Costs, State Participation & Obesity Treatment Policy Key Takeaways Medicare and Medicaid will launch voluntary pilot coverage for GLP-1 weight loss drugs ( Ozempic ,  Wegovy ,  Zepbound ,  Mounjaro ) starting 2026-2027 . The 5-year experiment requires participating plans to include structured diet/exercise coaching alongside medication . Current rules exclude weight loss drug coverage under Medicare, with limited Medicaid exceptions (13 states) . Annual costs per patient range $5,000-$7,000, projected Medicare spending could hit $35B by 2034 . Internal Trump administration conflict exists: CMS’s  Mehmet Oz  supports coverage, while HHS Secretary  Robert F. Kennedy Jr.  criticizes costs . The Policy Shift Hits Like a Diner Coffee at 3 AM Medicare, Medicaid plans to experiment with covering weight loss drugs The Trump administration...

Celsius Energy Drink Recall Alert: Accidental Alcohol in Silver-Top Blue Razz Cans – FDA Warning for FL, NY, OH, VA, WI, SC Key Takeaways Alcohol in Energy Drinks : Select Celsius Astro Vibe cans contain vodka seltzer due to a packaging error . Identification : Affected cans have silver lids (not black) and specific lot codes laser-etched on the bottom . States Impacted : Products shipped to Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia, Wisconsin . No Reported Harm : Zero illnesses or injuries confirmed as of July 31, 2025 . Refunds Available : Contact  consumerrelations@highnoonvodka.com  for reimbursement . The Assembly Line Shuffle Machines hum. Conveyor belts rattle. A packaging supplier shipped empty  Celsius  cans to High Noon’s facility. Vodka seltzer flowed into those cans. Labels stayed put. No one noticed. The factory kept moving . States in the Crosshairs Twelve-packs landed in eight states. Distributors in Florida, Michigan, New Y...

Vinay Prasad Exits FDA: Abrupt Resignation of CBER Director & Chief Medical Officer After 3 Months | Sarepta Gene Therapy Controversy, Political Pressure & Regulatory Impact Key Takeaways Abrupt Exit : Vinay Prasad resigned as FDA’s biologics chief after less than three months amid political pressure and drug approval controversies . Sarepta Controversy : His scrutiny of  Elevidys , a Duchenne muscular dystrophy therapy, led to shipment halts after a patient death, reversed days before his departure . Political Targeting : Right-wing activist  Laura Loomer  spearheaded a smear campaign, branding Prasad a “progressive saboteur” for past critiques of Trump and COVID policies . Scientific Clash : Prasad overruled FDA scientists on COVID vaccines, limiting boosters to high-risk groups, drawing ire from public health experts . The Resignation Heard ‘Round the Beltway Vinay Prasad quit on a Tuesday. The FDA’s biologics chief walked out after 89 days, a blip in bureaucra...

  Key Takeaways Coca-Cola's potential switch  to cane sugar follows political pressure but faces  economic hurdles  . Price disparity : High-fructose corn syrup costs  $0.35/lb  vs. cane sugar at  $1.01/lb , nearly triple. Farm impact : Eliminating corn syrup could wipe out  $5.1B in U.S. farm revenue  . Health equivalence : The FDA states  no nutritional difference  exists between the sweeteners . Consumer cost : Mexican Coke (cane sugar) costs  over 60% more  than U.S. corn-syrup versions . The President’s Truth Social Bombshell President Trump fired a post into the digital ether. He claimed Coca-Cola agreed to dump high-fructose corn syrup for "REAL Cane Sugar" in U.S. products. The announcement hit like a barstool declaration, loud, abrupt, short on details. Coca-Cola’s response? A terse nod to "new innovative offerings." No confirmation. No timeline. Just corporate speak wrapped in a question mark. The disconnect betw...

  Key Takeaways Sarepta Therapeutics stock plunged ~40% following a second patient death linked to its gene therapy Elevidys . FDA may pull Elevidys off the market as safety concerns mount; shipments halted for non-ambulatory patients . Therapy initially approved controversially in 2023 for ages 4-5, later expanded amid efficacy debates . Year-to-date stock loss exceeds 87%, erasing billions in market value . Duchenne muscular dystrophy patients face renewed uncertainty as treatment risks outweigh benefits for some . The Bloodbath on Nasdaq Sarepta Therapeutics stock cratered 40% in premarket trading June 16, 2025. It opened at $13.60, a far cry from its 52-week high of $150.48 . The collapse wasn't a surprise to those watching the ticker. Shares had been dying a slow death all year. By July, the year-to-date loss hit 87.5% . Shareholders stared at ruins. Trading volume exploded to 60 million shares. Average volume is 5.9 million . The market cap vaporized, $1.336 billion intraday....

  Key Takeaways 🚨  FDA Warning Issued : The FDA sent WHOOP a warning letter on July 14, 2025, declaring its Blood Pressure Insights (BPI) feature an unapproved medical device . ⚖️  Regulatory Dispute : WHOOP argues BPI is a wellness tool (exempt from FDA review), while the FDA insists blood pressure measurement is inherently clinical . 💡  How BPI Works : Uses morning heart rate, HRV, and blood flow patterns (calibrated via a cuff) to estimate daily systolic/diastolic ranges, not real-time readings . ⚠️  FDA’s Safety Concerns : Inaccurate readings could delay hypertension treatment, risking stroke or heart failure . 💰  Consumer Impact : BPI is a key selling point of WHOOP’s $359/year “Life” tier. Removal could devalue the subscription . ⏳  Current Status : BPI remains active in the U.S. as WHOOP contests the FDA’s stance . The FDA-WHOOP Clash Over Blood Pressure Insights What’s Happening? On July 14, 2025, the FDA sent WHOOP a formal warning letter. ...

  Key Takeaways Discreet design drives adoption : Zyn’s smoke-free, spit-free format enables covert nicotine use anywhere, fueling workplace and social acceptance . Tobacco giants pivot strategy : Philip Morris acquired Zyn-maker Swedish Match for $16B, targeting smoke-free dominance as cigarette sales decline . Youth appeal sparks backlash : Social media “Zynfluencers” and flavors like Citrus drive teen use, doubling youth adoption since 2023 . FDA balances harm reduction : Regulators authorized Zyn as safer than cigarettes but monitor youth uptake closely, creating market uncertainty . Market explodes past $4B : U.S. nicotine pouch sales could hit $49.5B by 2033, growing 32.5% yearly as flavors and strengths diversify . From Swedish Labs to American Lips: Zyn’s Origin Story Back in 2008, Swedish pharma firm Niconovum created the first tobacco-free nicotine pouch called Zonnic. They aimed to deliver cleaner nicotine without the cancer-causing junk in traditional tobacco. Swedish M...

  Key Takeaways RFK Jr.'s MAHA Agenda : HHS Secretary Robert F. Kennedy Jr. aims for all Americans to use wearables within 4 years to combat chronic disease through real-time health tracking . Behavioral Motivation : Wearables like  Fitbit  and  Apple Watch  boost physical activity and help manage conditions like diabetes by providing instant feedback on glucose/heart rates . Privacy Risks : Data breaches (e.g., 23andMe hack) and insurance misuse (e.g., premium hikes based on tracked vitals) are major concerns . Accuracy Gaps : Skin tone variations and motion artifacts can skew heart rate/sleep data; devices aren’t FDA-approved for diagnosis . Cost Barriers : Continuous glucose monitors cost $100–$300/month, creating accessibility issues for low-income groups . RFK Jr.’s Wearable Vision: Health Revolution or Privacy Pitfall? So yeah, Health Secretary Robert F. Kennedy Jr. dropped this big plan last week—like, he wants  every single American  strapped i...